<?xml version="1.0" encoding="UTF-8"?>
<p>Baloxavir has a novel mechanism of action, preventing the formation of new virions by blocking replication early in the influenza life cycle.
 <sup>
  <xref rid="R16" ref-type="bibr">16</xref>,
  <xref rid="R17" ref-type="bibr">17</xref>
 </sup> Two previous Japanese studies evaluating the use of baloxavir in children &lt;12 years old have been completed; however, both were small, open-label studies (JapicCTI-163417
 <sup>
  <xref rid="R24" ref-type="bibr">24</xref>
 </sup> and JapicCTI-173811). MiniSTONE-2 is the first global, phase III, randomized active controlled study designed to investigate the safety and efficacy of a single dose of baloxavir in children.
</p>
